Trial Profile
First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary) ; Vinorelbine (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Sep 2005 New trial record.